Discovery of MK-1220: A Macrocyclic Inhibitor of Hepatitis C Virus NS3/4A Protease with Improved Preclinical Plasma Exposure

[Image: see text] The discovery of MK-1220 is reported along with the development of a series of HCV NS3/4A protease inhibitors containing a P2 to P4 macrocyclic constraint with improved preclinical pharmacokinetics. Optimization of the P2 heterocycle substitution pattern as well as the P3 amino aci...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Rudd, Michael T., McCauley, John A., Butcher, John W., Romano, Joseph J., McIntyre, Charles J., Nguyen, Kevin T., Gilbert, Kevin F., Bush, Kimberly J., Holloway, M. Katharine, Swestock, John, Wan, Bang-Lin, Carroll, Steven S., DiMuzio, Jillian M., Graham, Donald J., Ludmerer, Steven W., Stahlhut, Mark W., Fandozzi, Christine M., Trainor, Nicole, Olsen, David B., Vacca, Joseph P., Liverton, Nigel J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Chemical Society 2011
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4017977/
https://ncbi.nlm.nih.gov/pubmed/24900304
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/ml1002426
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados